Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older~* Tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic therapy and for which no standard therapy exists~* Expansion cohort only: Advanced lymphoma confirmed by histopathology~* Measurable or evaluable disease according to RECIST for solid tumors or according to IWRC for NHL tumors~* ECOG Performance Status less than or equal to 2~* Life expectancy greater than 12 weeks in the opinion of the Investigator~Exclusion Criteria:~* Any active or uncontrolled infection~* NYHA Grade II or greater congestive heart failure~* History of myocardial infarction within 6 months prior to screening~* Prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy within 4 weeks prior to screening or 5 half-lives of the therapy, whichever is shorter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): IONIS-STAT3Rx

Based on this trial design, predict the completion outcome and termination type (if applicable).